To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes
Authors:
- 20 June 2023
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 82 (1) , 42-46
Abstract
Purpose Heart failure (HF) is a chronic disease that causes approximately 300,000 and 250,000 deaths per year in Europe and United States, respectively. Type 2 Diabetes Mellitus (T2DM) is one the major risk factors of HF, and the investigation of NT-proBNP might support the early identification of HF in T2DM sufferers. Nevertheless, this parameter is poorly investigated. Thus, we aimed to demographically and clinically characterize diabetic patients which were prescribed with NT-proBNP in the primary care setting. Methods Using a primary care database, we formed a cohort of patients aged ≥18 years diagnosed with T2DM between 2002 and 2021. A multivariate Cox model was adopted to assess the determinants associated with the prescription of NT-proBNP. Results Among 167,961 T2DM patients, 7558 (4.5%, 95% CI: 4.4–4.6) were prescribed with NT-proBNP. Males and increasing age were expectedly associated with a higher propensity to be prescribed with NT-proBNP. In addition, a significant association was found for those suffering from obesity, ischemic cardiomyopathy, stroke, atrial fibrillation, hypertension, and with a Charlson Index of 2+. Conclusion These determinants might contribute to investigate the NT-proBNP in T2DM sufferers. A decision support system to appropriately ease the prescription of NT-proBNP might be therefore implemented in primary care settings.Keywords
This publication has 18 references indexed in Scilit:
- Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE TrialDiabetes Care, 2017
- The Burden of Chronic Heart Failure in Primary Care in ItalyHigh Blood Pressure & Cardiovascular Prevention, 2017
- Primary care REFerral for EchocaRdiogram (REFER) in heart failure: a diagnostic accuracy studyBritish Journal of General Practice, 2016
- Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCirculation: Heart Failure, 2016
- The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care settingBMJ, 2015
- N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes StudyDiabetologia, 2014
- Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care†European Heart Journal, 2010
- State of the Art: Using Natriuretic Peptide Levels in Clinical PracticeEuropean Journal of Heart Failure, 2008
- Amino-Terminal Pro–B-Type Natriuretic Peptide Testing to Assist the Diagnostic Evaluation of Heart Failure in Symptomatic Primary Care PatientsThe American Journal of Cardiology, 2008
- Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Circulation, 2003